(Q34189897)

English

Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

0 references

Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

0 references

0 references

circulatory system

1 reference

based on heuristic

inferred from title

plaque psoriasis

1 reference

based on heuristic

inferred from title

author name string

T Tzellos

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

A Kyrgidis

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

C C Zouboulis

3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

publication date

8 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Journal of the European Academy of Dermatology and Venereology

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

622-627

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Psoriasis: epidemiology, clinical features, and quality of life

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04500.X

21 January 2018

Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04500.X

21 January 2018

Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04500.X

21 January 2018

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04500.X

21 January 2018

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04500.X

21 January 2018

Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04500.X

21 January 2018

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04500.X

21 January 2018

Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04500.X

21 January 2018

Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04500.X

21 January 2018

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04500.X

21 January 2018

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04500.X

21 January 2018

Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04500.X

21 January 2018

Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04500.X

21 January 2018

Bias in the one-step method for pooling study results.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04500.X

21 January 2018

Meta-analysis: impact of drug class on adherence to antihypertensives

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04500.X

21 January 2018

Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2012.04500.X

21 January 2018

Identifiers

10.1111/J.1468-3083.2012.04500.X

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

release_5ltojpw3xjayzh5jzqt6acabdu

1 reference

https://api.fatcat.wiki/v0/release/5ltojpw3xjayzh5jzqt6acabdu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34189897&oldid=1842896095"